Adicet Bio Inc
ACET
Get informed when a big investor buys or sells
+ FollowMarket Cap$75.72M
Close$
$3.51
56.9% downside
Current Fair Value
56.9% downsideOvervalued by 56.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $75.72 Million |
|---|---|
| Enterprise Value | $64.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.95 |
| Beta | 1.57 |
| Outstanding Shares | 10,744,621 |
Return
| Return on Equity | -77.70% |
|---|---|
| Return on Assets | -64.25% |
| Return on Invested Capital | -76.43% |
Valuation & Multiples
| P/E Ratio | -0.54 |
|---|---|
| PEG | 1.92 |
| Price to Sales | - |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.56 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-2.93
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-2.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 52,900▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.14%▼ 25.92% |
|---|---|
| Total Invested | $43.25M▼ 23.56% |
| Investors Holding | 490% |
ESG Score
No data
About Adicet Bio, Inc.
152 employees
CEO: Mr. Chen Schor BA, CPA, M.B.A. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell recepto...